Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780406 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL5203561 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL199463 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL199462 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL350996 | 1.00 | SLC1A2 (0.47) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| Hydrochloric Acid SCHEMBL2297672 | 0.98 | SLC1A2 (0.46) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| Hydrochloric Acid SCHEMBL2297675 | 0.98 | SLC1A2 (0.46) | SLC1A2AKR1C3AKR1C1MEN1BLM | |
| SCHEMBL851578 | 0.89 | MEN1 (0.50) | SLC1A2MEN1BLMKMT2A | |
| SCHEMBL16056887 | 0.89 | MEN1 (0.50) | SLC1A2MEN1BLMKMT2A | |
| SCHEMBL4074609 | 0.89 | MEN1 (0.50) | SLC1A2MEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 563 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-20160076058-A1 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | GENOMATICA, INC. | 2016-03-17 | — | — | US | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-8980843-B2 | Leptin agonist and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-17 | — | — | US | claimed |
| EP-1937710-B1 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF | SOCPRA SCIENCES SANTE ET HUMAINES S E C (CA) | 2012-10-17 | — | — | EP | claimed |
| US-20120129774-A1 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF | UNIVERSITE DE SHERBROOKE (CA) | 2012-05-24 | — | — | US | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| US-8076453-B2 | Kinin B1 receptor peptide agonists and uses thereof | Societe De Commercialisation Des Produits De La Recheche Appliquee-Socpra-Science Sante Et Humaines S.E.C. (CA) | 2011-12-13 | — | — | US | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| US-7884074-B2 | Compounds and methods for prevention and/or treatment of inflammation using the same | Ikaria Development Subsidiary Two, LLC (US) | 2011-02-08 | — | — | US | claimed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | claimed |
| US-20090054347-A1 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF | UNIVERSITE DE SHERBROOKE (CA) | 2009-02-26 | — | — | US | claimed |
| WO-2008147781-A2 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | LS9, INC. (US) | 2008-12-04 | — | — | WO | claimed |
| EP-1937710-A1 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF | Université de Sherbrooke (CA) | 2008-07-02 | — | — | EP | claimed |
| WO-2006128293-A1 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF | UNIVERSITé DE SHERBROOKE (CA) | 2006-12-07 | — | — | WO | claimed |
| EP-0732399-A2 | Chymotrypsin-like proteases and their inhibitors | CEPHALON, INC. (US) | 1996-09-18 | — | — | EP | claimed |
| EP-0518955-A4 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | — | 1993-09-22 | — | — | EP | claimed |
| WO-1993000359-A1 | MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0518955-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1992-12-23 | — | — | EP | claimed |
| WO-1991013904-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1991-09-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | SLC1A2 537/4885AKR1C3 2293/4885AKR1C1 1951/4885 |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NPR3, RXFP3, RXFP1 | SLC1A2 2110/4885AKR1C3 3045/4885AKR1C1 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.